CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4.
about
Relevance of tumor-infiltrating lymphocytes in breast cancerPathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy.A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models.Immunological off-target effects of standard treatments in gastrointestinal cancersAutophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity.Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas.Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment.Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns.Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.Microneedle-Assisted, DC-Targeted Codelivery of pTRP-2 and Adjuvant of Paclitaxel for Transcutaneous Immunotherapy.Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.Regulatory T-cell density and cytotoxic T lymphocyte density are associated with complete response to neoadjuvant paclitaxel and carboplatin chemoradiotherapy in gastric cancer
P2860
Q26795598-91D4491A-8604-48F9-8391-3DBCC0DAF26CQ33744706-329DD1A4-F60B-4B8A-84B7-9A928B084ECBQ36261283-09352AC9-64B8-40BA-9EF6-56A7E9A6CAF3Q36524227-4F04CB65-150F-4340-9AA7-B3C3EF79757DQ36903206-EE58F954-230F-4DF0-95DD-10276FDBBB01Q37126642-2B7F5946-4C2D-4ACD-8E61-7C15D5CA039AQ37404086-627E75CB-678E-4147-B867-A38D7DBE6323Q38034270-4485C14F-CD7C-4B9D-84EF-772CAB97F2B6Q38115968-0DC43A0C-C281-4407-A85E-79B2981CAF7AQ38167887-65CFBAC4-22B1-463B-AAA1-B525AF8AE4C6Q38525024-3A2FD587-FB34-40DD-B42E-28CD700DF19AQ41897007-118527BE-748D-4A64-843D-0BCA3A8F24ADQ42734547-8A97DA7C-BFDD-460A-84D9-64583E83429AQ42848419-5BC0C9C0-8C90-495C-8ABB-3B7E0C0E066AQ44209463-EB3CC471-E6CA-4418-B49E-D23B9331B117Q47346032-1E52FD9D-D768-4074-A0B8-82D56B1B747FQ48351402-7DD36CB7-46BE-41A2-89B3-3CFF7EEDDB54Q48535444-DD181A56-E69C-425D-B7D0-B97E9F908CFCQ57787105-BFD01D25-CE77-49E1-AA4C-3D62BC000F5E
P2860
CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
CD4+Foxp3+ regulatory T-cell i ...... ndent of toll-like receptor 4.
@en
CD4+Foxp3+ regulatory T-cell i ...... ndent of toll-like receptor 4.
@nl
type
label
CD4+Foxp3+ regulatory T-cell i ...... ndent of toll-like receptor 4.
@en
CD4+Foxp3+ regulatory T-cell i ...... ndent of toll-like receptor 4.
@nl
prefLabel
CD4+Foxp3+ regulatory T-cell i ...... ndent of toll-like receptor 4.
@en
CD4+Foxp3+ regulatory T-cell i ...... ndent of toll-like receptor 4.
@nl
P2093
P2860
P1476
CD4+Foxp3+ regulatory T-cell i ...... ndent of toll-like receptor 4.
@en
P2093
P2860
P304
P356
10.1111/J.1365-3083.2011.02514.X
P577
2011-04-01T00:00:00Z